Aptose Biosciences Announces Completion of Acquisition by Hanmi Pharmaceutical

Aptose Biosciences has closed its acquisition arrangement with Hanmi Pharmaceutical, delivering C$2.41 per share in cash, a 28% premium to the prior 30-day VWAP of C$1.88. The deal received shareholder and final court approval and has cleared necessary regulatory approvals in Korea, with Aptose shares expected to delist from the TSX around July 3, 2026. The transaction is a clear liquidity and control event for holders, supporting a positive near-term outlook for the stock.

Analysis

This is no longer a biotech catalyst trade; it is a settlement-and-liquidity event. The only edge left in APS/APTOF is the tiny residual spread versus cash, and that spread should be viewed as compensation for cross-border processing, currency conversion, and delisting friction rather than fundamental upside. For most accounts, the right move is to treat the position as effectively monetized and avoid carrying headline risk into the final trading/transfer window.

The real winner is Hanmi, which has converted a public, externally financed development asset into a controlled internal option. That matters because private ownership lets them slow-walk or re-sequence tuspetinib without market punishment, but it also removes public-market optionality: if the program needs more capital or partner validation later, Hanmi will bear the full financing burden. The second-order loser is any residual arb holder relying on borrow or stale quotes; borrow recall and forced buy-ins are the main short-squeeze risk into delisting, not a rerating of the drug story.

Time horizon is days, not months. The main falsifier is a delisting or settlement delay; if the exchange process slips or payment mechanics get messy, the cash spread can widen temporarily even though fundamental value is fixed. Beyond that, there is little to underwrite until Hanmi eventually discloses what it plans to do with the asset, which is a 6-18 month information vacuum rather than an investable public-market catalyst.

Key Decisions for Investors

• Flatten any residual APS/APTOF exposure into the final trading window; this is a liquidity/settlement event, not a continuation catalyst.
• If APTOF still trades at a meaningful discount to C$2.41 on the final session, consider only a very small, 1-5 day settlement arb long; size for operational risk, not headline spread capture.
• Do not initiate or maintain shorts in APS/APTOF into delisting; borrow recall and buy-in risk outweighs any remaining downside.
• Set a post-close alert for any settlement delay or delisting slip; if cash proceeds are not moving within the expected window, exit the arb and assume process risk has increased materially.
• No trade recommendation on Hanmi public proxies absent new disclosure; the equity value impact is too indirect until the company signals whether it will accelerate, partner, or pause the program.